4,901 trials
Overweight · Obesity · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Area Under the Concentration Time Curve From Time Zero to Time T, Where T is the Last Time Point With a Measurable Concentration [ AUC(0-tlast)]…
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve (AUC) of Edaravone — 2612; 2592; 2657; 2617 ng·h/mL
Sarcoma
Primary: Area Under the Concentration-time Curve From the Time Zero to the Last Non-zero Concentration (AUC0-t) of Selinexor — 2752; 3175; 3280; 3342 Nanograms*hour per…
Asthma
Primary: Maximum Observed Serum Concentration (Cmax) of Tezepelumab — 27.1 microgram per milliliter (mcg/mL)
Renal Impairment · Healthy Volunteers
Primary: Cmax: Maximum Observed Plasma Concentration for Mobocertinib and Its Active Metabolites (AP32960 and AP32914) — 17.1; 11.2; 12.2; 7.92 nanograms per milliliter(ng/mL)
Healthy
Primary: Part A: Number of Participants With Adverse Events — 4; 3; 4; 3 participants
Healthy · MDMA ('Ecstasy')
Primary: Responses to Affective Touch — -1.24; 0.12; 0.19; 0.25 units on a scale
Healthy Study Participants
Primary: Maximum Plasma Concentration (Cmax) for a Single Dose of Brivaracetam — 2.286; 1.989 micrograms per milliliter (μg/mL)
Radiation Dermatitis
Primary: Number of Participants With an Adverse Skin Event — 1 Participants
Healthy Adult Subjects
Primary: Area Under the Concentration Versus Time Curve From Zero up to Infinity (AUC0-inf) of Edaravone — 2165; 2209; 2073; 1955 ng·h/mL
COVID-19 · Pharmacokinetics · Safety
Primary: Number of Participants With Related Grade 2 or Higher Adverse Events — 6; 2; 27; 15 Participants — p=.70
Childhood Solid Neoplasm · Recurrent Childhood Anaplastic Large Cell Lymphoma · Recurrent Neuroblastoma
Primary: Maximum Tolerated Dose (MTD) of Crizotinib — 215 mg/m^2
Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Diffuse Intrinsic Pontine Glioma
Primary: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose of Adavosertib — 200 mg/m^2
Healthy
Primary: Cmax — 11.0; 107 ng/mL
Malignant Glioma · Recurrent Brain Neoplasm · Recurrent Childhood Central Nervous System Neoplasm
Primary: Number of Dose Limiting Toxicities of Selinexor — 0; 4; 1; 2 Participants